cal College Memorial Sloan Kettering Cancer Center,. • Disease Focus: Sickle Cell Anemia • Purpose: • Combine Angiocrine's E-CEL Technology with Sloan Kettering's gene correction technology to develop a curative therapy for sickle cell disease • Funds research, pre-clinical development and IND C\ [Angiocrin